BGI Genomics Co Ltd
300676
Company Profile
Business description
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Contact
21 Hongan Third Street
Dong
Huada Complex Park
Yantian District
Shenzhen518083
CHNT: +86 75536307065
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
3,702
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Microsoft’s earnings report is expected to touch on AI adoption and monetization.
stocks
World’s largest miner overvalued after solid quarter
The ongoing war is likely to keep commodity prices even more volatile than usual until it is resolved.
stocks
Hidden value in an expensive ASX
How investors can uncover value beyond the index heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,024.20 | 27.20 | -0.30% |
| CAC 40 | 8,233.20 | 76.77 | 0.94% |
| DAX 40 | 24,161.42 | 33.48 | -0.14% |
| Dow JONES (US) | 49,437.14 | 52.89 | -0.11% |
| FTSE 100 | 10,459.68 | 16.78 | -0.16% |
| HKSE | 25,915.20 | 248.04 | -0.95% |
| NASDAQ | 24,557.85 | 99.72 | -0.40% |
| Nikkei 225 | 59,140.23 | 445.63 | -0.75% |
| NZX 50 Index | 12,884.93 | 60.67 | -0.47% |
| S&P 500 | 7,130.65 | 7.25 | -0.10% |
| S&P/ASX 200 | 8,793.40 | 26.10 | -0.30% |
| SSE Composite Index | 4,093.25 | 13.01 | -0.32% |